Business Context and Reporting Period
This Form 8-K Current Report was filed by Mustang Bio, Inc. on April 18, 2022. The report discloses a significant corporate governance event: the appointment of an Interim Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Executive Appointment: On April 18, 2022, the Company appointed Eliot M. Lurier as Interim Chief Financial Officer.
- Compensation Structure: Mr. Lurier provides services via a consulting agreement with Danforth Advisors, LLC ("Danforth"). He receives no direct compensation from Mustang Bio, Inc.
- Background: Mr. Lurier previously served as CFO of the Joslin Diabetes Center, Inc. (2014–2020) and holds a B.S. in Accounting and CPA certification.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies. The document is strictly limited to the disclosure of the officer appointment and the associated consulting agreement.
Investor Verification Checklist
- Verify the terms of the "Danforth Consulting Agreement" (Exhibit 99.1) to understand the scope of services and indirect compensation arrangements.
- Confirm the duration of the "Interim" status for the new CFO and any plans for a permanent appointment.
- Review recent 10-Q or 10-K filings for the most current financial position, as this 8-K does not provide financial metrics.